• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

PCA Rx & Cost Plus Drugs Partner to Transform Drug Pricing Transparency

by Fred Pennic 12/18/2023 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Drug Pricing Transparency

What You Should Know:

– PCA Rx and Cost Plus Drugs, are joining forces to tackle the longstanding issue of opaque and inflated drug pricing in the US healthcare system.

– This landmark collaboration paves the way for greater transparency, accessibility, and affordability for employers and individuals nationwide.

Prioritizing Drug Pricing Transparency

By prioritizing transparency, this partnership empowers employers and members to make informed choices and fosters a more engaged healthcare community. It signifies a major leap forward in transforming the industry’s approach to drug pricing and paves the way for a more accessible and affordable healthcare system for all.

PCA Rx, known for its transparent PBM model, and Cost Plus Drugs, the brainchild of Mark Cuban focused on cost-plus pricing, share a mission to empower patients and employers with clear information about medication costs. This partnership combines their expertise to offer an unprecedented level of clarity in drug pricing, addressing a major pain point in the healthcare sector.

This collaboration actively seeks solutions to prescription affordability challenges. Kelly Cromer, PharmD, VP Operations & Clinical at PCA Rx, emphasizes, “PCA Rx and Cost Plus Drugs are committed to lowering drug prices and enhancing transparency, empowering individuals and employers to make informed healthcare decisions.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Drug-Pricing Transparency

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A: Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

White House Event Unveils CMS Health Tech Ecosystem Initiative

White House Event Unveils CMS Health Tech Ecosystem Initiative

Meaningful Use Penalties_Meaningful Use_Partial Code Free_Senators Urge CMS to Establish Clear Metrics for ICD-10 Testing

CMS Finalizes TEAM Model: A New Era of Value-Based Surgical Care

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low, But AI Dominates and $1B+ IPOs Emerge

Healthcare Investment Shifts in 1H 2025: AI Remains a Bright Spot Amidst Fundraising Decline

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low

Digital Health Faces Q2’25 Pullback: Funding Falls to 5-Year Low

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |